A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
1 report, 1 independent
Updated Aug 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Cabometyx was approved in combination with BMY's Opdivo, and Merck supplied Keytruda for an Exelixis study.Sub-event
Seeking FDA clearance for IND application for combination therapies.1 source
Keep exploring
The entities involved
-
Bristol-Myers Squibb
American pharmaceutical company
-
Exelixis
American biotechnology company
- FDA
Related events
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
Coverage
Newest first; wire copies grouped- Insider MonkeyExelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial We recently compiled a list of the 11 Cheap Biotech Stocks to Buy According to Hedge Funds. Exelixis, Inc. is one of them. Exelixis, Inc. (NASDAQ